IOL Chemicals & Pharmaceuticals Ltd logo

IOL Chemicals & Pharmaceuticals Ltd

IOLCP NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹5,118 Cr
Volatility
Moderate
P/E Ratio
30.08
EBITDA
₹290 Cr
Return on Equity
7.65%
Debt to Equity
0.08
Book Value
₹61.27
EPS
₹20.19
52W High
₹179.6
52W Low
₹67.19

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view IOL Chemicals & Pharmaceuticals Ltd insights

59 extracted metrics + investor summaries across FY15–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

3
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 22.1%
  • Promoter holding has increased by 4.80% over last quarter.

Weaknesses

3
  • Stock is trading at 2.81 times its book value
  • The company has delivered a poor sales growth of 3.35% over past five years.
  • Company has a low return on equity of 7.74% over last 3 years.

Growth Rate

Revenue Growth
11.36% ↘
Net Income Growth
36.10% ↗
Cash Flow Change
19.99% ↗
ROE
27.71% ↗
ROCE
21.69% ↘
EBITDA Margin (Avg.)
16.09% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 50d ago
AI opinion · based on fundamentals
Risk medium

IOL Chemicals & Pharmaceuticals trades at a market cap of ₹4,300 Cr with a PE of 30.5x and near-zero debt. The company has seen a sharp TTM profit recovery of 44% but carries a weak 5-year sales CAGR of just 3% and a subdued 3-year ROE of 8%.

Bull Case 8
  • Company is almost debt-free, providing financial flexibility and lower interest burden
  • TTM profit growth of 44% signals a meaningful earnings recovery after years of decline
  • Promoter holding increased by 4.86% in the last quarter, indicating insider confidence
  • Stock has delivered 53% returns over the past 1 year, reflecting strong momentum
  • 10-year compounded profit growth of 19% demonstrates long-term earnings capability
  • Healthy dividend payout of 22.1% shows commitment to returning capital to shareholders
  • 10-year sales CAGR of 15% indicates the company scaled well over the longer term
  • TTM sales growth of 12% suggests demand recovery after a sluggish 3-year period
Bear Case 8
  • 5-year compounded profit growth is -20%, indicating a prolonged earnings downcycle
  • 5-year sales CAGR of only 3% reflects persistently weak topline growth
  • 3-year ROE of just 8% is well below what quality pharma/chemical companies typically deliver
  • PE of 30.5x is expensive relative to the low single-digit 3-year sales CAGR of 2%
  • 3-year compounded profit growth of only 1% shows the recovery is very recent and unproven
  • Last year ROE of 8% and 3-year ROE of 8% show no improvement in capital efficiency
  • 5-year stock CAGR of just 2% suggests the market rewarded shareholders poorly over a medium-term horizon
  • Dividend yield of 0.7% offers limited income cushion at current valuations

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 50d ago
Neutral 1
  • Minor fire at Minoxidil unit Jun 11

    A minor fire at Unit-9B in Barnala on June 9, 2026 has suspended Minoxidil operations for 8–10 days. No injuries or significant property damage reported; all other units operating normally.

TL;DR: IOL Chemicals experienced a contained fire incident at one manufacturing unit with minimal impact—no injuries, no major property damage, and a short 8–10 day suspension limited to a single unit. The event is operationally insignificant given normal functioning across remaining facilities, and the outlook remains unchanged pending restoration completion.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
563
545
520
504
502
526
523
528
552
568
580
619
756
Expenses
490
481
476
454
452
484
476
465
490
510
523
527
653
Operating Profit
73
64
44
50
51
42
47
63
62
57
57
93
104
OPM %
13%
12%
9%
10%
10%
8%
9%
12%
11%
10%
10%
15%
14%
Other Income
7
7
8
8
7
6
4
5
7
7
-6
2
8
Interest
4
4
4
3
2
4
4
4
4
3
4
3
4
Depreciation
14
16
16
16
17
18
19
19
20
20
20
20
21
PBT
62
51
32
38
39
26
28
45
46
41
28
71
87
Tax %
25%
26%
28%
25%
24%
26%
26%
30%
25%
26%
25%
25%
26%
Net Profit
46
38
23
28
30
19
21
32
34
30
21
53
64
EPS in Rs
1.57
1.29
0.79
0.96
1.01
0.65
0.7
1.08
1.16
1.02
0.7
1.81
2.2
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
385
580
711
983
1,685
1,894
1,967
2,184
2,217
2,133
2,079
2,319
2,524
Expenses
373
529
608
863
1,276
1,321
1,375
1,927
1,990
1,901
1,877
2,049
2,213
Operating Profit
11
51
102
120
410
574
592
257
227
232
202
270
310
OPM %
2.9%
9%
14%
12%
24%
30%
30%
12%
10%
11%
10%
12%
12%
Other Income
1
1
1
6
10
16
24
17
25
30
22
9
11
Interest
59
61
68
64
51
21
6
8
16
16
15
15
14
Depreciation
29
30
30
30
32
36
39
43
46
63
72
80
82
PBT
-75
-39
6
31
336
533
571
223
189
183
138
184
226
Tax %
-12%
4%
21%
12%
30%
32%
22%
26%
26%
26%
27%
25%
—
Net Profit
-67
-40
5
28
237
361
445
166
140
135
101
138
168
EPS in Rs
-2.8
-1.42
0.17
0.99
8.32
12.7
15.15
5.64
4.77
4.61
3.44
4.69
5.73
Div. Payout %
0%
0%
0%
0%
0%
5%
8%
14%
17%
22%
23%
21%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
48
56
56
56
57
57
59
59
59
59
59
59
Reserves
160
129
132
160
417
757
1,202
1,332
1,448
1,553
1,629
1,740
Borrowings
400
453
447
422
284
59
3
44
80
33
117
135
Other Liabilities
94
135
182
214
184
297
347
526
434
600
577
653
Total Liabilities
702
772
817
852
942
1,170
1,610
1,960
2,021
2,244
2,382
2,587
Fixed Assets
403
400
374
406
412
469
512
561
751
933
1,170
1,181
CWIP
4
4
21
7
27
19
48
105
90
101
22
96
Investments
0
0
0
0
0
0
1
2
20
21
21
21
Other Assets
295
369
422
439
503
682
1,048
1,292
1,159
1,190
1,168
1,289
Total Assets
702
772
817
852
942
1,170
1,610
1,960
2,021
2,244
2,382
2,587
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
-47
18
83
120
273
471
380
91
123
290
179
214
Investing
-5
-27
-23
-50
-63
-184
-317
-121
-119
-191
-154
-198
Financing
50
9
-60
-70
-197
-272
-58
-2
-4
-92
46
-29
Net Cash Flow
-2
0
1
-1
13
15
4
-31
0
7
70
-13
Free Cash Flow
-53
-9
61
71
213
391
272
-60
-86
18
-34
44
CFO/OP
-413
34
82
105
83
102
88
60
75
144
97
93
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
31
55
58
54
43
52
56
79
83
81
90
95
Inventory Days
279
201
201
109
66
64
98
95
77
111
95
91
Days Payable
92
102
115
83
42
62
79
95
74
123
112
118
Cash Conversion Cycle
218
154
144
80
67
55
74
79
86
69
73
68
Working Capital Days
59
39
36
23
43
46
66
71
72
71
58
53
ROCE %
-3%
4%
12%
15%
56%
68%
54%
18%
14%
12%
9%
11%

Shareholding Pattern

As of Jun 2026
Promoters 62.28%
Public 26.95%
Others 5.47%
FIIs 4.87%
DIIs 0.43%
Total 100.00%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
43.69%
43.69%
43.69%
43.69%
43.69%
43.69%
43.69%
43.69%
48.19%
48.19%
48.19%
48.19%
48.19%
48.19%
48.19%
52.62%
52.62%
52.62%
52.62%
52.62%
57.48%
62.28%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
2.34%
2.18%
1.41%
1.39%
1.63%
1.49%
1.47%
2.59%
2.25%
2.08%
1.72%
4.87%
DIIs
0.04%
0.04%
0.36%
0.50%
0.02%
0.02%
0.06%
0.17%
0.02%
0.26%
0.36%
0.37%
0.30%
0.10%
0.08%
0.08%
0.07%
0.02%
0.04%
0.03%
0.02%
0.43%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
27.30%
28.03%
29.86%
30.15%
30.29%
31.15%
31.15%
30.92%
30.49%
29.28%
30.28%
30.63%
30.98%
31.48%
31.31%
31.23%
31.43%
30.22%
29.97%
30.51%
31.03%
26.95%
Others
28.97%
28.24%
26.08%
25.66%
25.99%
25.14%
25.10%
25.23%
21.30%
22.26%
18.84%
18.62%
19.12%
18.84%
18.79%
14.58%
14.40%
14.54%
15.12%
14.76%
9.74%
5.47%
No. of Shareholders
1,09,092
1,27,893
1,42,022
1,45,041
1,46,437
1,48,907
1,45,692
1,43,327
1,40,177
1,26,004
1,35,397
1,34,235
1,30,003
1,28,689
1,25,979
1,26,701
1,30,002
1,25,040
1,36,129
1,33,531
1,31,550
1,19,311

Documents

Frequently Asked Questions about IOL Chemicals & Pharmaceuticals Ltd

What does IOL Chemicals & Pharmaceuticals Ltd do?
IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market.[1] It is the largest player of Ibuprofen (pain killer) globally with a world market share of 35%.[2]
Where is IOL Chemicals & Pharmaceuticals Ltd (IOLCP) listed?
IOL Chemicals & Pharmaceuticals Ltd is listed on the Indian stock exchanges. It is listed on NSE: IOLCP and BSE: 524164. You can view its live share price, financials, and ratios on Tapetide.
Which sector does IOL Chemicals & Pharmaceuticals Ltd belong to?
IOL Chemicals & Pharmaceuticals Ltd operates in the Healthcare sector within the Pharmaceuticals & Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of IOL Chemicals & Pharmaceuticals Ltd?
IOL Chemicals & Pharmaceuticals Ltd has a market capitalisation of approximately ₹5117.65 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of IOL Chemicals & Pharmaceuticals Ltd?
The Price-to-Earnings (PE) ratio of IOL Chemicals & Pharmaceuticals Ltd is 30.08. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of IOL Chemicals & Pharmaceuticals Ltd?
Over the past 52 weeks, IOL Chemicals & Pharmaceuticals Ltd has traded between a low of ₹67.19 and a high of ₹179.6. This range helps investors understand the stock's price volatility and recent trading levels.
Does IOL Chemicals & Pharmaceuticals Ltd pay dividends?
Yes, IOL Chemicals & Pharmaceuticals Ltd has a dividend yield of 0.59%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of IOL Chemicals & Pharmaceuticals Ltd?
IOL Chemicals & Pharmaceuticals Ltd has a Return on Equity (ROE) of 7.65%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research IOL Chemicals & Pharmaceuticals Ltd on Tapetide?
On Tapetide, you can view IOL Chemicals & Pharmaceuticals Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market.[1] It is the largest player of Ibuprofen (pain killer) globally with a world market share of 35%.[2]

Website iolcp.com
Listed 2010-11-08
Face Value ₹ 2
Issued Size 29,35,27,510

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List